MEDIPOST speeds up its global commercialization of CARTISTEM by requesting official product approval in Malaysia2021/03/15STEM CELL THERAPEUTIC
MEDIPOST receives approval for processing the phase 3 clinical trial of CARTISTEM in Japan2021/02/15STEM CELL THERAPEUTIC
MEDIPOST completes the phase 1 clinical trial of its injectable drug for knee osteoarthritis, SMUP-IA-012020/11/16STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/07/07STEM CELL THERAPEUTIC
MEDIPOST’s Clinical Trial of Next-Generation Cell Therapy Product ‘SMUP-IA-01’ Makes Solid Progress2020/05/21STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/01/06STEM CELL THERAPEUTIC
MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan2019/12/09STEM CELL THERAPEUTIC
MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Treatment of Osteochondral Cartilage Defects in Ankle Joint2019/12/03STEM CELL THERAPEUTIC
MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTISTEM and new pipeline of products2019/11/14STEM CELL THERAPEUTIC
MEDIPOST Registers the Chinese Patent for a Mesenchymal Stem Cell Culture Method2019/10/23STEM CELL THERAPEUTIC
MEDIPOST Treats First Patient with Injectable Cell Therapeutic for Knee Osteoarthritis2019/10/17STEM CELL THERAPEUTIC
